CLX · Clorox Co · Financials

$86.40 -2.26 (-2.55%) At close · Oct 23

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$10.45B

120.92M

Volume · Oct 23 1.98M Avg daily vol (3M) 2.85M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$6.72B -5.4%

FY2026

Net Income

$587M -27.5%

FY2026

Gross Margin

42.32% -2.9pp

FY2026

Diluted EPS

$4.81 -26.2%

FY2026

Operating Cash Flow

$612M -37.6%

FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2027 (G)	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	-3.1%	-1.8%	+1.6%	—	$6.72B	$7.1B	$7.09B	$7.39B	$7.11B	$7.34B	$6.72B	$6.21B	$6.12B	$5.97B	$5.76B	$5.66B	$5.51B	$5.62B	$5.47B	$5.23B	$5.23B	—	—
Cost of Revenue	-4.7%	-1.3%	+2.1%	—	$3.88B	$3.89B	$4.05B	$4.48B	$4.56B	$4.14B	$3.66B	$3.49B	$3.45B	$3.3B	$3.16B	$3.19B	$3.16B	$3.14B	$3.16B	$2.96B	$2.92B	$2.95B	$3.1B
Gross Profit	-0.7%	-2.3%	+0.9%	—	$2.84B	$3.21B	$3.05B	$2.91B	$2.55B	$3.2B	$3.06B	$2.73B	$2.68B	$2.67B	$2.6B	$2.47B	$2.36B	$2.39B	$2.3B	$2.27B	$2.32B	$2.2B	$2.18B
Gross Margin	—	—	—	—	42.32%	45.23%	42.97%	39.36%	35.81%	43.58%	45.57%	43.9%	43.68%	44.72%	45.1%	43.59%	42.73%	42.52%	42.14%	43.45%	44.31%	—	—
Research & Development	-5.6%	-4.9%	-1.9%	—	$116M	$121M	$126M	$138M	$132M	$149M	$145M	$136M	$132M	$135M	$141M	$136M	$125M	$130M	$121M	$115M	$118M	$113M	$111M
Selling, General & Administrative	-3.4%	+1.2%	+2.8%	—	$1.07B	$1.12B	$1.17B	$1.18B	$954M	$1B	$969M	$856M	$837M	$810M	$806M	$798M	$751M	$793M	$798M	$735M	$734M	$703M	$690M
Amortization of Intangibles	-2.3%	-2.6%	+13.3%	—	$28M	$21M	$29M	$30M	$31M	$32M	$14M	$15M	$10M	$10M	$8M	$12M	$15M	$15M	$9M	$14M	$221M	$219M	—
Depreciation & Amortization	+1.5%	+3.2%	+4.1%	—	$247M	$219M	$235M	$236M	$224M	$211M	$180M	$180M	$166M	$163M	$165M	$169M	$177M	$182M	$178M	$173M	$183M	$188M	$205M
Restructuring Charges	—	—	—	—	—	$0	$29M	$71M	—	—	—	—	—	—	—	$2M	$0	$0	—	—	—	—	—
Interest Expense	+13.0%	+5.6%	+4.0%	—	$130M	$88M	$90M	$90M	$106M	$99M	$99M	$97M	$85M	$88M	$88M	$100M	$103M	$122M	$125M	$123M	$139M	$161M	$168M
Interest Income	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$4M	$3M	$3M	$3M	$3M	$3M	$4M	$12M
Other Non-Operating Income	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$7M	$13M	$10M	$4M	$13M	$23M	$29M	—	—
Gain on Sales of Real Estate	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$13M	—	—	—
Equity in Earnings of Unconsolidated Entities	-9.1%	-9.7%	-14.9%	—	$3M	$4M	$5M	$4M	$6M	$5M	$20M	$15M	$12M	$19M	$15M	$14M	$13M	$12M	$11M	$8M	$9M	$8M	$8M
Investment Income (Loss)	+21.3%	0.0%	—	—	$25M	$18M	$20M	$14M	-$21M	$25M	$3M	$6M	—	—	—	—	—	—	—	—	—	—	—
Pretax Income	+49.2%	-2.5%	-2.1%	—	$791M	$1.08B	$398M	$238M	$607M	$900M	$1.19B	$1.02B	$1.05B	$1.03B	$983M	$921M	$884M	—	—	—	—	—	—
Income Tax	+35.1%	+1.0%	-5.5%	—	$190M	$254M	$106M	$77M	$136M	$181M	$246M	$204M	$231M	$330M	$335M	$315M	$305M	$279M	$248M	$276M	$322M	$274M	$232M
Net Income	+57.9%	-3.7%	-1.0%	—	$587M	$810M	$280M	$149M	$462M	$710M	$939M	$820M	$823M	$701M	$648M	$580M	$558M	$572M	$541M	$557M	$603M	$537M	$461M
Net Margin	—	—	—	—	8.74%	11.4%	3.95%	2.02%	6.5%	9.67%	13.97%	13.2%	13.44%	11.74%	11.25%	10.26%	10.12%	10.17%	9.89%	10.65%	11.52%	—	—
Net Income Attributable to Noncontrolling Interests	+5.3%	+9.2%	—	—	$14M	$14M	$12M	$12M	$9M	$9M	$0	$0	—	—	—	—	—	—	—	—	—	—	—
Comprehensive Income	+63.2%	-6.1%	+0.1%	—	$587M	$808M	$618M	$135M	$529M	$804M	$901M	$804M	$819M	$728M	$580M	$495M	$508M	$601M	$395M	$678M	—	—	—
EPS (Basic) USD/shares	+58.5%	-3.2%	-0.4%	—	$4.82	$6.56	$2.26	$1.21	$3.75	$5.66	$7.46	$6.42	$6.37	$5.43	$5.01	$4.45	$4.31	$4.37	$4.14	$4.06	$4.28	$3.82	$3.27
EPS (Diluted) USD/shares	+58.9%	-2.9%	-0.2%	$5.41 – $5.71	$4.81^G	$6.52^G	$2.25^G	$1.20^G	$3.73^G	$5.58^G	$7.36^G	$6.32	$6.26	$5.33	$4.92	$4.37	$4.23	$4.30	$4.09	$4.02	$4.24	$3.79	$3.23
Shares Outstanding (Basic Avg) shares	-0.5%	-0.6%	-0.6%	—	121.78M	123.53M	124.17M	123.59M	123.11M	125.57M	125.83M	127.73M	129.29M	128.95M	129.47M	130.31M	129.56M	131.08M	130.85M	136.7M	140.27M	139.02M	139.63M
Shares Outstanding (Diluted Avg) shares	-0.6%	-0.8%	-0.8%	—	122.13M	124.29M	124.8M	124.18M	123.91M	127.3M	127.67M	129.79M	131.58M	131.57M	131.72M	132.78M	131.74M	132.97M	132.31M	138.1M	141.53M	140.17M	141.2M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2026: $5.86B in buybacks, $8.27B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Latest reported total

USD 5,100,000,000

As of Jun 30, 2026

Tracked instruments

Loans, facilities and note series

Annual baseline

Jun 30, 2026

Latest approved annual total

Reported total debt history

As of	Reported label	Amount	Source
2026-06-30	debt	USD 5,100,000,000	10-K filed 2026-08-07 As of June 30, 2026, the Company had approximately $5.1 billion of debt.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Finance lease liabilities	2026-06-30	USD 78,000,000	10-K filed 2026-08-07
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current finance lease liabilities USD 16,000,000 Noncurrent finance lease liabilities USD 62,000,000
Long-term debt, including current maturities	2026-06-30	USD 3,982,000,000	10-K filed 2026-08-07
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current portion of long-term debt USD 1,000,000 Noncurrent debt carrying amount USD 3,981,000,000
Operating lease liabilities	2026-06-30	USD 452,000,000	10-K filed 2026-08-07
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 86,000,000 Noncurrent operating lease liabilities USD 366,000,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

2 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Some sections could not be verified in 1 agreement document. Other restrictions or tests may apply.

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

1.800% Senior Notes due 2030

Note · The Clorox Company

Reference: 1.800% Senior Notes due 2030

Active

Original principal: USD 500,000,000
Outstanding: —
Commitment: —
Availability: —
Maturity: —

Covenant terms for this agreement are not yet verified.

Documents and filing history

SeriesInstrument · EX-4.1 · 2020-05-08 — EX-4.1

Issuance · 2020-05-08 Original principal USD 500,000,000 Exact source document Parent 8-K filing · 2020-05-08
WHEREAS, the Issuer wishes to issue senior notes designated as 1.800% Senior Notes due 2030 in the aggregate principal amount of $500,000,000 (the “Notes”);

Issuer evidence: EIGHTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of May 8, 2020, is between The Clorox Company, a Delaware corporation (the “Issuer”), and Wells Fargo Bank, National Association, a national banking association (“Trustee”).

Supporting evidence: WHEREAS, the Issuer wishes to issue senior notes designated as 1.800% Senior Notes due 2030 in the aggregate principal amount of $500,000,000 (the “Notes”);

Supporting evidence: WHEREAS, the Issuer wishes to issue senior notes designated as 1.800% Senior Notes due 2030 in the aggregate principal amount of $500,000,000 (the “Notes”);

4.700% Senior Notes due 2031

Note · The Clorox Company

Reference: 4.700% Senior Notes due 2031

Active

Original principal: USD 550,000,000
Outstanding: —
Commitment: —
Availability: —
Maturity: —

Last reported interest terms: 4.7% Reported 2026-05-11 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history

Issuance · 8-K · 2026-05-11 — 8-K

Issuance · 2026-05-11 Original principal USD 550,000,000 Exact source document Parent 8-K filing · 2026-05-11
On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Issuer evidence: On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Supporting evidence: On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Supporting evidence: On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

4.950% Senior Notes due 2033

Note · The Clorox Company

Reference: 4.950% Senior Notes due 2033

Active

Original principal: USD 400,000,000
Outstanding: —
Commitment: —
Availability: —
Maturity: —

Last reported interest terms: 4.95% Reported 2026-05-11 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history

Issuance · 8-K · 2026-05-11 — 8-K

Issuance · 2026-05-11 Original principal USD 400,000,000 Exact source document Parent 8-K filing · 2026-05-11
On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Issuer evidence: On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Supporting evidence: On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Supporting evidence: On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

5.250% Senior Notes due 2036

Note · The Clorox Company

Reference: 5.250% Senior Notes due 2036

Active

Original principal: USD 550,000,000
Outstanding: —
Commitment: —
Availability: —
Maturity: —

Last reported interest terms: 5.25% Reported 2026-05-11 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history

Issuance · 8-K · 2026-05-11 — 8-K

Issuance · 2026-05-11 Original principal USD 550,000,000 Exact source document Parent 8-K filing · 2026-05-11
On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Issuer evidence: On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Supporting evidence: On May 6, 2026, The Clorox Company (the “Company”) executed an underwriting agreement in connection with the sale of an aggregate principal amount of $550,000,000 of its 4.700% Senior Notes due 2031 (the “2031 Notes”), an aggregate principal amount of $400,000,000 of its 4.950% Senior Notes due 2033 (the “2033 Notes”) and an aggregate principal amount of $550,000,000 of its 5.250% Senior Notes due 2036 (taken together with the 2031 Notes and the 2033 Notes, the “Securities”), in an underwritten registered public offering (the “Underwriting Agreement”). The offering closed on May 11, 2026. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

2.13×

Peer median 2.70×

EV/EBIT

—

Peer median 26.06×

P/E (TTM)

17.96×

Peer median 33.82×

Peer medians compare against the 11 similar-size Household & Personal Products companies (of 30 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2026	FY2025	FY2024
Health and Wellness	$2,697,000,000	$2,697,000,000	$2,485,000,000
Household	$1,787,000,000	$2,001,000,000	$1,950,000,000
Lifestyle	$1,123,000,000	$1,303,000,000	$1,275,000,000
International	$1,113,000,000	$1,065,000,000	$1,162,000,000

By Geography (USD)

Component	FY2026	FY2025	FY2024
United States	$5,629,000,000	$6,080,000,000	$5,956,000,000
Non Us	$1,091,000,000	$1,024,000,000	$1,137,000,000

Key facts CIK 21076 CUSIP 189054109 13F (30d) 274 filings 260 filers Visit website Investor relations